Author: Bikdeli, Behnood; Madhavan, Mahesh V.; Gupta, Aakriti; Jimenez, David; Burton, John R.; Der Nigoghossian, Caroline; Chuich, Taylor; Nouri, Shayan Nabavi; Dreyfus, Isaac; Driggin, Elissa; Sethi, Sanjum; Sehgal, Kartik; Chatterjee, Saurav; Ageno, Walter; Madjid, Mohammad; Guo, Yutao; Tang, Liang V.; Hu, Yu; Bertoletti, Laurent; Giri, Jay; Cushman, Mary; Quéré, Isabelle; Dimakakos, Evangelos P.; Gibson, C. Michael; Lippi, Giuseppe; Favaloro, Emmanuel J.; Fareed, Jawed; Tafur, Alfonso J.; Francese, Dominic P.; Batra, Jaya; Falanga, Anna; Clerkin, Kevin J.; Uriel, Nir; Kirtane, Ajay; McLintock, Claire; Hunt, Beverley J.; Spyropoulos, Alex C.; Barnes, Geoffrey D.; Eikelboom, John W.; Weinberg, Ido; Schulman, Sam; Carrier, Marc; Piazza, Gregory; Beckman, Joshua A.; Leon, Martin B.; Stone, Gregg W.; Rosenkranz, Stephan; Goldhaber, Samuel Z.; Parikh, Sahil A.; Monreal, Manuel; Krumholz, Harlan M.; Konstantinides, Stavros V.; Weitz, Jeffrey I.; Lip, Gregory Y. H.
Title: Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research Cord-id: 9b5cuyae Document date: 2020_5_30
ID: 9b5cuyae
Snippet: Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithromb
Document: Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.
Search related documents:
Co phrase search for related documents- abnormal coagulation and acute disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
- abnormal coagulation and acute limb: 1
- abnormal coagulation and acute limb ischemia: 1
- absence presence and acetylsalicylic acid: 1
- absence presence and action mechanism: 1, 2, 3, 4, 5, 6
- absence presence and activate leukocyte: 1
- absence presence and activator transducer: 1
- absence presence and active form: 1, 2
- absence presence and active study: 1, 2, 3
- absence presence and acute disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acetylsalicylic acid and active form: 1
- acetylsalicylic acid and acute coronary syndrome: 1, 2
- acetylsalicylic acid and acute disease: 1, 2, 3
- action mechanism and acute disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- activator transducer and acute disease: 1, 2, 3, 4
- active form and acute disease: 1, 2, 3
- active study and acute disease: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date